HIF1A and neoplasm: The upfront use of TACE in HCC with a high tumor burden may sometimes be incomplete, increasing tumor hypoxia and the upregulation of hypoxia-inducible factor-1α (HIF1α),VEGFs, and PDGFRs [21].